Neurotez Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Crowdfunding
- Financing Rounds
-
8
Neurotez General Information
Description
Operator of a biopharmaceutical company intended to serve Alzheimer's patients characterized by hyperleptinemia. The company offers screening, identification, and characterization of treatments using biochemical, molecular, and cell biology in vivo models, enabling medical practitioners to improve the lives of their patients and serve the public responsibly.
Contact Information
Website
www.neurotez.comCorporate Office
- 111 Town Square Place
- Suite 1201
- Jersey City, NJ 07310
- United States
Corporate Office
- 111 Town Square Place
- Suite 1201
- Jersey City, NJ 07310
- United States
Neurotez Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Neurotez Comparisons
Industry
Financing
Details
Neurotez Competitors (16)
One of Neurotez’s 16 competitors is Centrexion Therapeutics, a Venture Capital-Backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Centrexion Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| Xalud Therapeutics | Venture Capital-Backed | New York, NY | ||||
| Maxona Pharmaceuticals | Venture Capital-Backed | Malvern, PA |
Neurotez Patents
Neurotez Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2014165043-A1 | Fragments, mutants and chimeric fusion proteins of leptin for treating alzheimer's disease | Inactive | 13-Mar-2013 | ||
| US-20140088000-A1 | Leptin rescues neurons from alzheimer's disease related pathways triggered by lipid burden | Inactive | 27-Sep-2012 | ||
| US-20130065825-A1 | Compositions and methods for delaying senescence or cell death in neurons | Inactive | 14-Sep-2011 | ||
| US-20120231457-A1 | Compositions and methods for assessing a genetic risk of developing late-onset alzheimer's disease (load) | Inactive | 10-Mar-2011 | ||
| AU-2009313562-A1 | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta | Active | 04-Nov-2008 | A61K38/22 |
Neurotez Signals
Neurotez Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Neurotez FAQs
-
When was Neurotez founded?
Neurotez was founded in 2005.
-
Where is Neurotez headquartered?
Neurotez is headquartered in Jersey City, NJ.
-
What is the size of Neurotez?
Neurotez has 7 total employees.
-
What industry is Neurotez in?
Neurotez’s primary industry is Drug Discovery.
-
Is Neurotez a private or public company?
Neurotez is a Private company.
-
What is Neurotez’s current revenue?
The current revenue for Neurotez is .
-
How much funding has Neurotez raised over time?
Neurotez has raised $150M.
-
Who are Neurotez’s investors?
CRG Capital Partners has invested in Neurotez.
-
Who are Neurotez’s competitors?
Centrexion Therapeutics, Bristol-Myers Squibb, Ability Pharma, Xalud Therapeutics, and Maxona Pharmaceuticals are some of the 16 competitors of Neurotez.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process